Drugs / mRNA-0217/S001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05916261 | Apr 2023 → Nov 2026 expected | pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-0217/S001 | “mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection” NCT05916261 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-0217/S001 vaccine encoding personalized tumor neoantigens” NCT05916261 ↗ |